Potassium cyanide protects Escherichia coli from complement killing by the inhibition of C3 convertase activity.
The exact mechanism by which deposited C5b-9 complexes kill Gram-negative bacteria is unclear. It has been proposed that during complement activation the membrane attack complex triggers an energy dependent process in Gram-negative bacteria that mediates destruction of the inner membrane. This observation in part resulted from the survival of Gram-negative bacteria that were incubated with an uncoupler (DNP) or an inhibitor (KCN) of oxidative phosphorylation during complement activation. In a reexamination of this issue we employed potassium cyanide (KCN) to block energy dependent pathways and observed a dose dependent inhibition of C9 uptake on E. coli J5 during serum incubation, suggesting that cyanide was interfering with complement activation. To verify the effect on complement activation we chose specifically to study the effects of KCN on the C3 convertase of the classical pathway. Sensitized sheep erythrocytes were employed as our model system. This system allowed us to construct a series of stable intermediates that were used to test the effect of cyanide on the formation and activity of precursors of the classical pathway C3 convertase. The data illustrate that the concentrations of potassium cyanide that inhibit complement killing of J5 also inhibit C3 convertase activity on sensitized sheep erythrocytes. The results of this study refute the principal observation made by other investigators, that potassium cyanide protects bacteria from complement killing by inhibiting bacterial energy dependent pathways that spark inner membrane destruction. A better scenario is that the organisms survive because cyanide inhibits complement activation.
Department of Microbiology, Howard University College of Medicine, Washington, D.C.
E F
EF
Bloch
M
M
Rahbar
A K
AK
Wright
A M
AM
Patterson
R F
RF
Souza
C H
CH
Hammer
T A
TA
Gaither
K A
KA
Joiner
D000818:Animals; D003167:Complement Activation / Q000187:drug effects*; D050577:Complement C3-C5 Convertases / Q000037:antagonists & inhibitors / Q000187:drug effects*; D003186:Complement C9 / Q000037:antagonists & inhibitors*; D003602:Cytotoxicity, Immunologic; D004305:Dose-Response Relationship, Drug; D004926:Escherichia coli / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D011190:Potassium Cyanide / Q000494:pharmacology*
D003186:Complement C9; D050577:Complement C3-C5 Convertases; D011190:Potassium Cyanide